Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated:  12/2/2014
2352
mi
from 98109
Richmond, VA
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated: 12/2/2014
Virginia Commonwealth University Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Status: Enrolling
Updated:  2/5/2015
705
mi
from 98109
Stanford, CA
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Status: Enrolling
Updated: 2/5/2015
Stanford University School of Medicine
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated:  2/13/2015
1495
mi
from 98109
Kansas City, KA
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated: 2/13/2015
University of Kansas Medical Center
1495
mi
from 98109
Kansas City, KA
Click here to add this to my saved trials
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Status: Enrolling
Updated:  2/18/2015
2432
mi
from 98109
New Haven, CT
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Status: Enrolling
Updated: 2/18/2015
Yale Cancer Center
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1779
mi
from 98109
Little Rock, AR
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1779
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
988
mi
from 98109
Fountain Valley, CA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
988
mi
from 98109
Fountain Valley, CA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
979
mi
from 98109
Los Angeles, CA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
979
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2402
mi
from 98109
New Milford, CT
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2402
mi
from 98109
New Milford, CT
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2322
mi
from 98109
Washington,
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2707
mi
from 98109
Boca Raton, FL
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2707
mi
from 98109
Boca Raton, FL
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2679
mi
from 98109
Honolulu, HI
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2679
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1733
mi
from 98109
Chicago, IL
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2399
mi
from 98109
Morristown, NJ
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2399
mi
from 98109
Morristown, NJ
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2110
mi
from 98109
Buffalo, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2402
mi
from 98109
New York, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2154
mi
from 98109
Rochester, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2154
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
145
mi
from 98109
Portland, OR
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
145
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
2347
mi
from 98109
Upland, PA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
2347
mi
from 98109
Upland, PA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1766
mi
from 98109
Austin, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1766
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1661
mi
from 98109
Grapevine, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1661
mi
from 98109
Grapevine, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1892
mi
from 98109
Houston, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
1743
mi
from 98109
Temple, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
1743
mi
from 98109
Temple, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
12
mi
from 98109
Seattle, WA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
12
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
6918
mi
from 98109
Buenos Aires,
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
6918
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
674
mi
from 98109
Berkeley, CA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Alta Bates Summit Medical Center-Herrick
674
mi
from 98109
Berkeley, CA
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
953
mi
from 98109
Burbank, CA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Providence Saint-Joseph Medical Center
953
mi
from 98109
Burbank, CA
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
2531
mi
from 98109
Daytona Beach, FL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Halifax Health- Center for Oncology
2531
mi
from 98109
Daytona Beach, FL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
1730
mi
from 98109
Chicago, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
1719
mi
from 98109
Park Ridge, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Oncology Specialists
1719
mi
from 98109
Park Ridge, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
2394
mi
from 98109
Hackensack, NJ
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Hackensack Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
2161
mi
from 98109
Morgantown, WV
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
West Virginia University, WVU Healthcare
2161
mi
from 98109
Morgantown, WV
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
1723
mi
from 98109
Maywood, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Loyola University Chicago
1723
mi
from 98109
Maywood, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
2454
mi
from 98109
Worcester, MA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
University of Massachusetts Worcester
2454
mi
from 98109
Worcester, MA
Click here to add this to my saved trials
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated:  6/19/2015
1892
mi
from 98109
Houston, TX
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated: 6/19/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated:  7/2/2015
1892
mi
from 98109
Houston, TX
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated: 7/2/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1113
mi
from 98109
Scottsdale, AZ
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mayo Clinic Scottsdale
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
2457
mi
from 98109
Jacksonville, FL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mayo Clinic, Jacksonville
2457
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1708
mi
from 98109
Aurora, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Rush-Copley Cancer Care Center
1708
mi
from 98109
Aurora, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1713
mi
from 98109
Bloomington, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
St. Joseph Medical Center
1713
mi
from 98109
Bloomington, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1662
mi
from 98109
Canton, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Graham Hospital
1662
mi
from 98109
Canton, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1616
mi
from 98109
Carthage, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Memorial Hospital
1616
mi
from 98109
Carthage, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1692
mi
from 98109
Eureka, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Eureka Community Hospital
1692
mi
from 98109
Eureka, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1634
mi
from 98109
Galesburg, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Galesburg Clinic, PC
1634
mi
from 98109
Galesburg, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1634
mi
from 98109
Galesburg, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Galesburg Cottage Hospital
1634
mi
from 98109
Galesburg, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1669
mi
from 98109
Havana, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mason District Hospital
1669
mi
from 98109
Havana, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1694
mi
from 98109
Hopedale, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Hopedale Medical Complex
1694
mi
from 98109
Hopedale, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1720
mi
from 98109
Joliet, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Joliet Oncology-Hematology Associates, Limited - West
1720
mi
from 98109
Joliet, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1636
mi
from 98109
Macomb, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
McDonough District Hospital
1636
mi
from 98109
Macomb, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1611
mi
from 98109
Moline, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
1611
mi
from 98109
Moline, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
1712
mi
from 98109
Normal, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Community Cancer Center
1712
mi
from 98109
Normal, IL
Click here to add this to my saved trials